ReviewCancer treatment reviews2008
Multi-functional nanocarriers to overcome tumor drug resistance.
Review in Cancer treatment reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 403 citations in OpenAlex.
- Advances in Carbon Nanotubes: Revolutionizing Cancer Diagnosis and Targeted Therapy.Current drug metabolism · 2026Review
- Assessment of the potential and application of BeScientific reports · 2025Article
- Biosynthesis and Multifaceted Characterization ofACS omega · 2024Article
- ROS-responsive polyprodrug micelles carrying suicide genes in combination with chemotherapy and gene therapy for prostate cancer treatment.RSC advances · 2024Article
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Article
- Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.Journal of nanobiotechnology · 2023Review
- Mesoporous Silica Nanoparticles as a Gene Delivery Platform for Cancer Therapy.Pharmaceutics · 2023Review
- Antiviral and Antibacterial Sulfated Polysaccharide-Chitosan Nanocomposite Particles as a Drug Carrier.Molecules (Basel, Switzerland) · 2023Article
- Nanoparticle drug delivery systems for synergistic delivery of tumor therapy.Frontiers in pharmacology · 2023Review
- Enzyme-responsive smart nanocarriers for targeted chemotherapy: an overview.Drug delivery and translational research · 2022Review
- DFT investigation on the application of pure and doped XRoyal Society open science · 2022Article
- High efficacy of tamoxifen-loaded L-lysine coated magnetic iron oxide nanoparticles in cell cycle arrest and anti-cancer activity for breast cancer therapy.BioImpacts : BI · 2022Article
- A plasmon-enhanced theranostic nanoplatform for synergistic chemo-phototherapy of hypoxic tumors in the NIR-II window.Chemical science · 2021Article
- An understanding of mitochondria and its role in targeting nanocarriers for diagnosis and treatment of cancer.Asian journal of pharmaceutical sciences · 2021Review
- Multi-Functionalized Nanomaterials and Nanoparticles for Diagnosis and Treatment of Retinoblastoma.Biosensors · 2021Review
- Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Nanomaterials for Protein Delivery in Anticancer Applications.Pharmaceutics · 2021Review
- Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement.Frontiers in immunology · 2021Article
- Toxicity of Carbon Nanomaterials and Their Potential Application as Drug Delivery Systems: In Vitro Studies in Caco-2 and MCF-7 Cell Lines.Nanomaterials (Basel, Switzerland) · 2020Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that lower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and light) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.